Replies to post #807629 on NorthWest Biotherapeutics Inc (NWBO)

[seekinganswers]

Bro.... just..... ughhhhhh

[sentiment_stocks]

I wasn't sure what was meant by the European IT changeover, so of course, I had to look it up, as it pertains to MHRA.

What came back is that for the UK:

UK Clinical Trials Regulation (MHRA): New comprehensive UK regulations for clinical trials will come into full effect on April 28, 2026. These reforms, developed in collaboration with the Health Research Authority (HRA), aim to align the UK more closely with international research community terminology (e.g., using "modification" instead of "amendment") and streamline processes. MHRA leveraged digital transformation to support this new framework, though a specific IT platform ("RegulatoryConnect") was wound down in late 2025 in favor of a future replacement that aligns with the agency's broader data and AI strategy.

and for the EU:

EU Variations Guidelines (EMA/EC): New European Commission (EC) guidelines for post-approval changes to marketing authorizations for medicinal products will apply to all variation applications submitted to the European Medicines Agency (EMA) from January 15, 2026.
This includes the mandatory use of an updated electronic application form (eAF).
The applicability of the new variation type (IA, IB, II) will be based on the implementation date in the manufacturer's quality management system, not the submission date.

So I'm not sure what this means for your AI's theory.